Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from China SXT Pharmaceuticals ( (SXTC) ).
On January 9, 2026, China SXT Pharmaceuticals, Inc. entered into a securities purchase agreement with an institutional investor for a registered direct offering comprising 12,000,000 Class A ordinary shares and 54,666,666 pre-funded warrants, part of a broader 66,666,666-share (or equivalent pre-funded warrant) deal priced at $0.15 per share. The offering, conducted under the company’s effective Form F-3 shelf registration, closed on January 13, 2026 and generated approximately $9.11 million in net proceeds, which the company plans to use for general corporate purposes. The pre-funded warrants, exercisable at $0.001 per share and subject to a 9.99% beneficial ownership cap, provide the investor with significant additional equity exposure, underscoring the company’s reliance on capital markets for funding and implying potential future dilution for existing shareholders as China SXT strengthens its balance sheet and supports ongoing operations.
More about China SXT Pharmaceuticals
Founded in 2005 and headquartered in Taizhou City, Jiangsu Province, China SXT Pharmaceuticals, Inc. is an innovative pharmaceutical company focused on the research, development, manufacture, marketing and sales of traditional Chinese medicine pieces, a form of processed Traditional Chinese Medicine prepared for immediate use.
Average Trading Volume: 5,061,623
Technical Sentiment Signal: Sell
Current Market Cap: $17.52M
Learn more about SXTC stock on TipRanks’ Stock Analysis page.